Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13815124 | 0.98 | EPHX1 (0.42) | EPHX1PAOXS1PR2S1PR4S1PR1 | |
| SCHEMBL20706483 | 0.84 | TSHR (0.52) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL20281606 | 0.84 | TSHR (0.52) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL20134437 | 0.84 | TSHR (0.52) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL7775065 | 0.84 | TSHR (0.52) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL10000678 | 0.84 | TSHR (0.52) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL7778097 | 0.84 | TSHR (0.52) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL24508687 | 0.84 | ALDH1A1 (0.33) | EPHX1ALDH1A1 | |
| SCHEMBL10045229 | 0.84 | CYP2C19 (0.48) | PAOXANPEPERAP2ALDH1A1TSHR | |
| SCHEMBL19133264 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524212-B2 | Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20130034607-A1 | TABLET | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-07 | — | — | US | disclosed |
| US-8173114-B2 | An agent for promoting excretion of an accumulative chlorine compound comprising a pharmaceutically acceptable anion exchange resin, which is a novel agent that is for promoting the excretion of an accumulative chlorine compound and is | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-08 | — | — | US | disclosed |
| US-7879869-B2 | Anion exchange resins e.g. colestimide; anticholesterol and antidiabetic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100055066-A1 | Agent for prophylactic and/or therapeutic treatment of diabetes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20090252794-A1 | TABLET | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090110655-A1 | PROPHYLACTIC AND/OR THERAPEUTIC DRUG FOR NONALCOHOLIC STEATOHEPATITIS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20070212325-A1 | Insulin Resistance-Improving Agent | MITSUBISHI PHARMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110655-A1 | PROPHYLACTIC AND/OR THERAPEUTIC DRUG FOR NONALCOHOLIC STEATOHEPATITIS | SLC10A1, SLC10A2, FABP1 | EPHX1 525/4885PAOX 494/4885S1PR2 564/4885 |
| US-20090252794-A1 | TABLET | SLC10A2, SI, TMPRSS15 | EPHX1 1723/4885PAOX 4748/4885S1PR2 1568/4885 |
| US-20070212325-A1 | Insulin Resistance-Improving Agent | GPR119, SLC2A8, IAPP | EPHX1 3864/4885PAOX 1464/4885S1PR2 2748/4885 |
| US-20130034607-A1 | TABLET | SLC10A2, SI, TMPRSS15 | EPHX1 1723/4885PAOX 4748/4885S1PR2 1568/4885 |
| US-20100055066-A1 | Agent for prophylactic and/or therapeutic treatment of diabetes | GPR119, IAPP, GSTO1 | EPHX1 445/4885PAOX 658/4885S1PR2 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.